Ropeginterferon alfa-2b-njft (P1101)

DRUG2 trials

Sponsors

PharmaEssentia

Conditions

Essential ThrombocythemiaPolycythemia Vera

Phase 2

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Active, not recruitingNCT05482971

PharmaEssentiaEssential Thrombocythemia

Start: 2022-09-29End: 2027-03-31Updated: 2025-08-13

Phase 3

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Active, not recruitingNCT05481151

PharmaEssentiaPolycythemia Vera

Start: 2022-10-26End: 2027-07-31Updated: 2025-08-13

Related Papers

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)

The Lancet Regional Health - Americas2026-06-10

Integrated analysis of the ropeginterferon alfa-2b clinical program in essential thrombocythemia to demonstrate molecular and hematologic responses with safety profile information across treatment lines, ethnicities, and driver mutation types.

Journal of Clinical Oncology2026-05-27

A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial

Frontiers in Medicine2025-04-172 citations

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

2024-03-0411 citations

A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera

Blood2023-11-022 citations

EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.

Journal of Clinical Oncology2023-06-011 citations